RALPH A. TRIPP
Professor, Georgia Research Alliance Chair of Animal Health Vaccine Development, GRA Eminent Scholar

Research interests include understanding the mechanisms of immunity and disease pathogenesis associated with respiratory virus infection, and using this information to develop therapeutic protocols and vaccines that will confer long-term protective immunity.

RECENT PUBLICATIONS

Search PubMed for "tripp, ra"

Liu Y, Haas DL, Poore S, Isakovic S, Gahan M, Mahalingam S, Fu ZF, Tripp RA. 2009. Human metapneumovirus establishes persistent infection in the lungs of mice and is reactivated by glucocorticoid treatment. J Virol, 83(13):6837-48.

Alvarez R, Elbashir S, Borland T, Toudjarska I, Hadwiger P, John M, Roehl I, Shulga Morskyaya S, Martinello R, Kahn J, Van Ranst M, Tripp RA, Devincenzo JP, Pandey R, Maier M, Nechiv L, Manoharan M, Koteliansky V, Meyers R. 2009. RNAi-Mediated Silencing of the Respiratory Syncytial Virus Nucleocapsid Defines a Potent Anti-Viral Strategy. Antimicrob Agents Chemother.

Oshansky CM, Krunkosky TM, Barber J, Jones LP, Tripp RA. 2009. Respiratory syncytial virus proteins modulate suppressors of cytokine signaling 1 and 3 and the type I interferon response to infection by a toll-like receptor pathway. Viral Immunol, 22(3):147-61.

Miao C, Radu GU, Caidi H, Tripp RA, Anderson LJ, Haynes LM. 2009. Treatment with respiratory syncytial virus G glycoprotein monoclonal antibody or F(ab')2 components mediates reduced pulmonary inflammation in mice. J Gen Virol, 90(Pt 5):1119-23.

Oshansky CM, Zhang W, Moore E, Tripp RA. 2009. The host response and molecular pathogenesis associated with respiratory syncytial virus infection. Future Microbiol, 4:279-97.

Murawski MR, Bowen GN, Cerny AM, Anderson LJ, Haynes LM, Tripp RA, Kurt-Jones EA, Finberg RW. 2009. Respiratory syncytial virus activates innate immunity through Toll-like receptor 2. J Virol, 83(3):1492-500.

Tripp RA, Tompkins SM. 2009. Therapeutic Applications of RNAi for Silencing Virus Replication. Methods Mol Biol, 555:43-61.

Driskell JD, Seto AG, Jones LP, Jokela S, Dluhy RA, Zhao YP, Tripp RA. 2008. Rapid microRNA (miRNA) detection and classification via surface-enhanced Raman spectroscopy (SERS). Biosens Bioelectron, 24(4):923-8.

Zhang W, Tripp RA. 2008. RNA interference inhibits respiratory syncytial virus replication and disease pathogenesis without inhibiting priming of the memory immune response. J Virol, 82(24):12221-31.

Moore EC, Barber J, Tripp RA. 2008. Respiratory syncytial virus (RSV) attachment and nonstructural proteins modify the type I interferon response associated with suppressor of cytokine signaling (SOCS) proteins and IFN-stimulated gene-15 (ISG15). Virol J, 5:116.

Tripp RA, Tompkins SM. 2008. Recombinant vaccines for influenza virus. Curr Opin Investig Drugs, 9(8):836-45.

Shanmukh S, Jones L, Zhao YP, Driskell JD, Tripp RA, Dluhy RA. 2008. Identification and classification of respiratory syncytial virus (RSV) strains by surface-enhanced Raman spectroscopy and multivariate statistical techniques. Anal Bioanal Chem, 390(6):1551-5.

Birkness KA, Guarner J, Sable SB, Tripp RA, Kellar KL, Bartlett J, Quinn FD.2007. An in vitro model of the leukocyte interactions associated with granuloma formation in Mycobacterium tuberculosis infection. Immunol Cell Biol, 85(2):160-8.

Tripp RA, Alvarez R, Anderson B, Jones L, Weeks C, Chen W. 2007. Bioconjugated nanoparticle detection of respiratory syncytial virus infection. Int J Nanomedicine, 2(1):117-24.

Mahalingam, S., Schwarze, J., Zaid, A., Nissen, M., Sloots, T., Tauro, S., Storer, J., Alvarez, R. and Tripp, R. A. 2006. Perspective on the host response to human metapneumovirus infection: what can we learn from respiratory syncytial virus infections? Microbes and Infection, 8(1):285-93.

Li, X. Q., Fu, Z. F., Alvarez, R., Henderson, C. and Tripp, R. A. 2006. Respiratory syncytial virus (RSV) infects neuronal cells and processes that innervate the lung by a process involving RSV G protein. Journal of Virology, 80(1):537-40.

Harcourt, J., Alvarez, R., Jones, L. P., Henderson, C., Anderson, L. J. and Tripp, R. A. 2006. Respiratory syncytial virus G protein and G protein CX3C motif adversely affect CX3CR1+ T cell responses. Journal of Immunology, 176(3):1600-8.

Agrawal, A., Zhang, C., Byassee, T., Tripp, R. A. and Nie, S. 2006. Counting single native biomolecules and intact viruses with color-coded nanoparticles. Analytical Chemistry, 78(4):1061-70.

Tripp, R. A., Oshansky, C. and Alvarez, R. 2005. Cytokines and respiratory syncytial virus (RSV) infection. Proceedings of the American Thoracic Society, 2:147-149.

Tripp, R. A. et al. 2005. Monoclonal antibodies to SARS-associated coronavirus (SARS-CoV): Identification of neutralizing and antibodies reactive to S, N, M and E viral proteins. Journal of Virological Methods, 128:21-8.

Agrawal, A., Tripp, R. A., Anderson, L. J. and Nie, S. 2005. Real-time detection of virus particles and viral protein expression with two-color nanoparticle probes. Journal of Virology, 79(13):8625-8.

Alvarez, R. and Tripp, R. A. 2005. The immune response to human metapneumovirus is associated with aberrant immunity and impaired virus clearance in BALB/c mice. Journal of Virology, 79(10):5971-8.

Alvarez, R., Harrod, K. S., Shieh, W. J., Zaki, S. and Tripp, R. A. 2004. Human metapneumovirus persists in BALB/c mice despite the presence of neutralizing antibodies. Journal of Virology, 78(24):14003-11.

Harcourt, J. L., Karron, R. A. and Tripp, R. A. 2004. Anti-G protein antibody responses to respiratory syncytial virus infection or vaccination are associated with inhibition of G protein CX3C-CX3CR1 binding and leukocyte chemotaxis. Journal of Infectious Diseases, 190(11):1936-40.

Alvarez, R., Jones, L. P., Seal, B. S., Kapczynski, D. R. and Tripp, R. A. 2004. Serological cross-reactivity of members of the Metapneumovirus genus. Virus Research, 105(1):67-73.

Tripp, R. A. 2004. Pathogenesis of respiratory syncytial virus infection. Viral Immunology, 17(2):165-81. Review.

Harcourt, J. L., Anderson L. J., Sullender W. and Tripp, R. A. 2004. Pulmonary delivery of respiratory syncytial virus DNA vaccines using macroaggregated albumin particles. Vaccine, 22(17-18):2248-60.

Tripp, R. A. 2004. The brume surrounding respiratory syncytial virus persistence. American Journal of Respiratory and Critical Care Medicine, 169(7):778-9.

Haynes, L. M., Jones, L. P., Barskey, A., Anderson, L. J. and Tripp, R. A. 2003. Enhanced Disease and Pulmonary Eosinophilia Associated with Formalin-Inactivated Respiratory Syncytial Virus Vaccination Are Linked to G Glycoprotein CX3C-CX3CR1 Interaction and Expression of Substance P, Journal of Virology, S77(18):9831-44.

Tripp, R. A., Dakhama, A., Gelfand, E., and Anderson, L. J. 2003. The G glycoprotein of respiratory syncytial virus depresses respiratory rates through the CX3C motif and substance P. Journal of Virology, 77:6580.

Harcourt, J. L., Brown M. P., Anderson L. J. and Tripp, R. A. 2003. CD40 ligand (CD154) improves the durability of respiratory syncytial virus DNA vaccination in BALB/c mice. Vaccine, 21:2964.

Tripp, R. A., 2003. Role of cytokines in the development and maintenance of memory T cells during respiratory viral infection, Current Pharmaceutical Design, 9:51.

Tripp, R. A., Barskey, A., Goss, L. and Anderson, L. J. 2002. Substance P receptor expression on lymphocytes is associated with the immune response to respiratory syncytial virus infection. Journal of Neuroimmunology, 129(1-2): 141-53.

Email
ratripp@uga.edu

Office
201 AHRC
706-542-1557

Tripp Lab Page
www.vet.uga.edu/id/tripp

Center for Disease Intervention

Degrees
PhD, Oregon State University, 1989